Ardena’s Post

View organization page for Ardena, graphic

12,474 followers

This week in our #ArdenaExpertInsights series, we explore the development of amorphous solid dispersions (ASDs) to tackle solubility and bioavailability challenges in new chemical entities (NCEs). In this Q&A, Oluwatomide Adeoye, Formulation Scientist, and Timothy Pas, Group Leader - Formulation Development and Production at Ardena, explain how ASDs enhance solubility, dissolution rates, and bioavailability, turning poorly soluble NCEs into effective oral medications. Learn about the key role of polymer matrix selection in preventing API recrystallization, and the main manufacturing technologies like spray drying and hot melt extrusion. At Ardena, our ASD expertise supports your drug development journey from early clinical stages onwards. Read the full Q&A below, and stay tuned for more insights from our experts on key drug development topics! #Ardena #PharmaceuticalDevelopment #AmorphousSolidDispersions #ASD #DrugDevelopment

To view or add a comment, sign in

Explore topics